세계의 mRNA 백신 및 치료제 시장 : 용도 분야별, 적응 질환별, 지역별-업계 동향 및 예측(-2035년)
mRNA Vaccine and Therapeutics Market by Application Area, Target Disease Indication and Geographical Regions : Industry Trends and Global Forecasts, Till 2035
상품코드:1624835
리서치사:Roots Analysis
발행일:2025년 01월
페이지 정보:영문 343 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 mRNA 백신 및 치료제 시장 규모는 주로 감염증 치료를 목적으로 하는 mRNA 백신 및 치료제의 승인이 예상됨에 따라 2035년까지 19억 9,000만 달러 규모에 이를 것으로 예측됩니다.
메신저 리보 핵산(mRNA)은 단일 가닥 리보 핵산(RNA)의 일종이며 단백질 생산을 위한 유전 정보 전달에 중요한 역할을합니다. mRNA는 DNA 가닥에서 리보솜으로 단백질 합성을 위한 코딩 명령어를 운반하며, 이러한 명령어가 번역되어 기능적 단백질로 처리됩니다.
최근 몇 년동안 mRNA 기술은 다양한 질병과 장애를 예방하고 치료하기 위한 제약 업계에 혁명을 가져 왔습니다. 코로나19 백신의 성공은 mRNA 백신과 치료제의 길을 열었습니다. 지난 몇 년간 mRNA 백신 및 치료제과 관련된 170개 이상의 임상시험이 등록된 것은 주목할 만합니다. 여러 전임상 및 임상 연구가 이러한 플랫폼의 유효성을 보여주고 있으며, 지난 2년간 다양한 연구 논문이 발표되었습니다. 이는 이해관계자가 이 영역에서 광범위한 개발 노력을 하고 있음을 보여줍니다. 현재 45개 이상의 업계 관계자들이 폭넓은 적응증의 mRNA 의약품 후보 개발에 힘쓰고 있습니다.
COVID-19 백신의 성공, 연구 활동의 활성화, mRNA 의약품 후보의 풍부한 파이프라인은 향후 10년간 세계의 mRNA 백신 및 치료제 시장을 견인할 가능성이 높다고 보여지고 있습니다.
이 보고서는 세계의 mRNA 백신 및 치료제 시장에 대해 조사했으며, 시장 개요와 함께 용도 분야별, 적응 질환별, 지역별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.
목차
제1장 서문
제2장 조사 방법
제3장 경제 및 기타 프로젝트 특유의 고려 사항
제4장 주요 요약
제5장 서문
제6장 시장 상황
제7장 경쟁 구도
제8장 기업 경쟁력 분석
제8장 유럽에 본사를 둔 mRNA 백신 및 치료제 개발자
제8장 아시아태평양 및 기타 지역에 본사를 둔 mRNA 백신 및 치료제 개발자
제9장 기업 프로파일
제10장 대기업 제약회사의 대처
제11장 스타트업의 건강 지표
제12장 임상시험 분석
제13장 파트너십 및 협업
제14장 자금 조달 및 투자 분석
제15장 특허 분석
제16장 시장 영향 분석 : 촉진요인, 억제요인, 기회, 과제
제17장 세계의 mRNA 백신 및 치료제 시장
제18장 mRNA 백신 및 치료제 시장 : 용도 분야별
제19장 mRNA 백신 및 치료제 시장 : 적응 질환별
제20장 mRNA 백신 및 치료제 시장 : 지역별
제21장 결론
제22장 주요 인사이트
제23장 부록 1 : 표 형식의 데이터
제24장 부록 2 : 기업 및 단체 일람
AJY
영문 목차
영문목차
MRNA VACCINE AND THERAPEUTICS MARKET: OVERVIEW
As per Roots Analysis, the global mRNA vaccine and therapeutics market is estimated to be worth USD 1.99 billion by 2035, primarily driven by the anticipated approval of mRNA vaccines and therapeutics intended for the treatment of infectious diseases.
The market sizing and opportunity analysis has been segmented across the following parameters:
Application Area
COVID-19
Other Indications
Target Disease Indication
Influenza
Respiratory Syncytial Virus Infection
Cytomegalovirus Diseases
Key Geographical Regions
North America
Europe
Asia-Pacific
Latin America
Rest of the World
MRNA VACCINE AND THERAPEUTICS MARKET: GROWTH AND TRENDS
Messenger ribonucleic acid (mRNA) is a form of single-stranded ribonucleic acid (RNA) that is crucial role in transferring genetic information for protein production. The mRNA carries the coding instructions for protein synthesis from a DNA strand to the ribosomes, where these instructions are translated and processed into functional proteins.
In recent years, mRNA technology has revolutionized the pharmaceutical industry to prevent and treat a wide array of diseases and disorders. The success of COVID-19 vaccines has paved the path for mRNA vaccines and therapeutics. It is worth highlighting that, in the past few years, more than 170 clinical trials related to mRNA-based therapeutics / vaccines have been registered. Multiple preclinical and clinical studies show the efficacy of these platforms which have been published in the last two years across different research articles. This demonstrates the extensive development efforts being undertaken by stakeholders in this domain. At present, over 45 industry players are engaged in the development of mRNA drug candidates for a wide range of disease indications.
The success of COVID-19 vaccines, growing research activity and the rich pipeline of mRNA drug candidates is likely to drive the global mRNA vaccine and therapeutics market in the coming decade.
MRNA VACCINE AND THERAPEUTICS MARKET: KEY INSIGHTS
The report delves into the current state of the mRNA vaccine and therapeutics market and identifies potential growth opportunities within the industry. Some key findings from the report include:
1. Presently, over 235 mRNA drug candidates are available in the market or under development; majority of these drug candidates are vaccines using lipid nanoparticles as delivery systems.
2. The pipeline features several drugs, which are being investigated across different phases of development; 60% of the drug candidates are designed to be administered via intramuscular routes.
3. The current market landscape of mRNA vaccine and therapeutics developers is fragmented, featuring the presence of both new entrants and established players; majority of these players are based in the US.
4. Stakeholders are actively upgrading their existing capabilities to further enhance their respective product pipeline and comply with the evolving industry benchmarks.
5. The growing interest of stakeholders is evident from the surge in partnership activity; clinical trial agreements emerged as the most prevalent partnership model adopted by drug developers.
6. Several investors, having realized the opportunity within this upcoming segment, have invested over USD 11 billion across various funding rounds.
7. More than 345,000 patients have been recruited / enrolled in clinical trials registered for various mRNA-based therapies, across different geographies.
8. Over 430 patents related to mRNA vaccine and therapeutics have been filed / granted by industry and non-industry stakeholders, indicating the growing intellectual capital in this domain.
9. Big pharma players have undertaken several initiatives, ranging from proprietary product development to strategic investments, to tap the lucrative opportunity in this rapidly growing market.
10. The projected opportunity for mRNA vaccine and therapeutics market is likely to be driven by the increasing research and development for mRNA-based drugs focused on non-COVID indications.
MRNA VACCINE AND THERAPEUTICS MARKET: KEY SEGMENTS
Several indications, such as Influenza, Respiratory Syncytial Virus, Cytomegalovirus, are the Expected to Drive the mRNA Vaccine and Therapeutics Market
Based on the application area, the market is segmented into COVID-19 and other indications. Owing to their proven efficacy against the COVID-19 infection, the vaccines and therapeutics developed for COVID-19 infection have captured the majority of the market share. However, the anticipated approval of mRNA vaccines for other indications is likely to drive the market in the coming decade.
Currently, Influenza Segment Occupies the Largest Share of the mRNA Vaccine and Therapeutics Market
Based on the target disease indication, the market is segmented into influenza, respiratory syncytial virus infection and cytomegalovirus diseases. It is worth highlighting that the vaccines and therapeutics developed for influenza are likely to drive the market in the coming decade. This can be attributed to the rise in investment in the research and development of influenza vaccines, along with growing awareness among governments and non-profit organizations about the importance of influenza prevention and control.
North America Accounts for the Largest Share of the Market
Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Latin America and Rest of the World. It is worth highlighting that the market for North America holds the maximum share of the mRNA vaccines and therapeutics market. This trend is likely to remain the same in the coming decade.
Example Players in the mRNA Vaccine and Therapeutics Market
Arcturus Therapeutics
BioNTech
CureVac
Ethris
IMMORNA
Moderna
Providence Therapeutics
RNACure
Suzhou Abogen Biosciences
Turn Biotechnologies
Gennova
Innovac Therapeutics
Kernal Biologics
Pantherna Therapeutics
pHion Therapeutics
Recode Therapeutics
Rejuvenation Technologies
RNAimmune
Strand Therapeutics
Walvax
Ziphius Vaccines
Primary Research Overview
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:
Business Development Manager, Canvax
Senior Director, Business Development, eTheRNA
Team Leader, GC Biopharma
MRNA VACCINE AND THERAPEUTICS MARKET: RESEARCH COVERAGE
Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the mRNA vaccine and therapeutics market, focusing on key market segments, including [A] application area, [B] target disease indication and [C] key geographical regions.
Market Landscape (Drug Therapies): A comprehensive evaluation of mRNA therapeutics and vaccines, considering various parameters, such as [A] phase of development, [B] type of drug candidate, [C] therapeutic area, [D] type of delivery system, [E] type of molecule encoded and [F] route of administration.
Market Landscape (Drug Developers): A comprehensive evaluation of companies involved in the development of mRNA vaccine and therapeutics, considering various parameters, such as [A] year of establishment, [B] company size (in terms of number of employees), [C] location of headquarters, [D] regional landscape and [E] key players engaged in this domain.
Company Competitiveness Analysis: A comprehensive competitive analysis of mRNA vaccine and therapeutic developers, examining factors such as [A] developer strength, [B] pipeline strength and [C] number of therapeutic areas targeted.
Company Profiles: In-depth profiles of key industry players engaged in the development of mRNA vaccine and therapeutics, focusing on [A] company overviews, [B] financial information, [C] mRNA vaccines and therapeutics pipeline, [D] recent developments and [E] an informed future outlook.
Big Pharma Analysis: A comprehensive examination of various mRNA focused initiatives undertaken by major pharmaceutical companies. It includes a heat map representation that highlights mRNA therapeutics and vaccines under development (in partnership with core mRNA-focused entities), along with information on [A] funding amount raised, [B] partnership activity, and [C] diversity of product portfolio, as well as a spider web representation, comparing the initiatives of big pharmaceutical players on the basis of multiple relevant parameters.
Start-up Health Indexing: An analysis of the startup companies engaged in this domain based on several relevant parameters, such as [A] number of candidates in discovery, [B] preclinical and clinical phases of development. In addition, it provides details on amount raised, number of investors and number of deals inked.
Clinical Trial Analysis: Examination of completed, ongoing, and planned clinical studies of various mRNA vaccines and therapeutics based on several relevant parameters, such as [A] trial registration year, [B] trial status, [C] trial phase, [D] therapeutic area, [E] study design, [F] type of sponsor / collaborator, [G] leading industry players (in terms of number of trials conducted), [H] enrolled patient population and [I] geography.
Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2013, based on several relevant parameters, such as year of partnership, type of partnership, therapeutic area, most active players (in terms of number of deals inked) and regional distribution of partnership activity.
Funding and Investment Analysis: A detailed evaluation of the investments made in the mRNA vaccines and therapeutics domain, encompassing seed financing, venture capital, IPOs, secondary offerings, debt, grants and other offerings based on several parameters, such as [A] year of funding, [B] type of funding, [C] amount invested, therapeutic area, most active players (in terms of number of funding instances and amount invested) and key investors (in terms of number of funding instances).
Patent Analysis: Detailed analysis of various patents filed / granted related to mRNA therapeutics and vaccines several relevant parameters, such as [A] type of patent, [B] publication year, [C] geographical region, [D] CPC symbols, [E] leading industry players (in terms of the number of patents filed / granted) and [F] patent valuation.
Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting market growth.
KEY QUESTIONS ANSWERED IN THIS REPORT
How many companies are currently engaged in this market?
Which are the leading companies in this market?
What kind of partnership models are commonly adopted by industry stakeholders?
What amount has been invested in this domain?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?
REASONS TO BUY THIS REPORT
The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
ADDITIONAL BENEFITS
Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
10% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older
TABLE OF CONTENTS
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Research Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Future Estimates
3.2.2. Currency Coverage and Foreign Exchange Rate
3.2.2.1. Major Currencies Affecting the Market
3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
3.2.2.4. Strategies for Mitigating Foreign Exchange Risks
3.2.3. Trade Policies
3.2.3.1. Impact of Trade Barriers on the Market
3.2.3.2. Strategies for Mitigating the
Risks associated with Trade Barriers
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. mRNA Therapeutics
5.2.1. Advantages of mRNA Therapeutics
5.2.2. Key Applications of mRNA Therapeutics
5.3. mRNA Vaccines
5.3.1. Advantages of mRNA Vaccines
5.3.2. Key Applications of mRNA Vaccines
5.4. mRNA Delivery Routes
5.5. mRNA Delivery Strategies
5.6. Key Challenges Associated with mRNA Vaccine and Therapeutics
5.7. Future Perspectives
6. MARKET LANDSCAPE
6.1. Chapter Overview
6.2. mRNA Vaccine and Therapeutics: Overall Market Landscape
6.2.1. Analysis by Phase of Development
6.2.2. Analysis by Type of Drug Candidate
6.2.3. Analysis by Therapeutic Area
6.2.4. Analysis by Phase of Development and Therapeutic Area
6.2.5. Analysis by Type of Delivery System
6.2.6. Analysis by Type of Molecule Encoded
6.2.7. Analysis by Route of Administration
6.2.8. Analysis by Therapeutic Area and Route of Administration
6.2.9. Analysis by Phase of Development, Therapeutic Area and Route of Administration
7. COMPETITIVE LANDSCAPE
7.1. Chapter Overview
7.2. mRNA Vaccine and Therapeutics: List of Developers
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Key Players: Analysis by Number of Drug Candidates
7.2.5. Key Players: Analysis by Phase of Development
7.2.6. Key Players: Analysis by Therapeutic Area
8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Parameters
8.3. Methodology
8.4. mRNA Vaccine and Therapeutics Developers: Company Competitiveness Analysis
8.4.1. mRNA Vaccine and Therapeutics Developers based in North America
8. 4.2. mRNA Vaccine and Therapeutics Developers based in Europe
8. 4.3. mRNA Vaccine and Therapeutics Developers based in Asia-Pacific and Rest of the World
9. COMPANY PROFILES
9.1. Chapter Overview
9.2. Leading Companies in mRNA Vaccine and Therapeutics Market
9.2.1. Arcturus Therapeutics
9.2.1.1. Company Overview
9.2.1.2. Financial Information
9.2.1.3. Pipeline Overview
9.2.1.4. Recent Developments and Future Outlook
9.2.2. BioNTech
9.2.2.1. Company Overview
9.2.2.2. Financial Information
9.2.2.3. Pipeline Overview
9.2.2.4. Recent Developments and Future Outlook
9.2.3. CureVac
9.2.3.1. Company Overview
9.2.3.2. Financial Information
9.2.3.3. Pipeline Overview
9.2.3.4. Recent Developments and Future Outlook
9.2.4. Ethris
9.2.4.1. Company Overview
9.2.4.2. Pipeline Overview
9.2.4.3. Recent Developments and Future Outlook
9.2.5. Immorna
9.2.5.1. Company Overview
9.2.5.2. Pipeline Overview
9.2.5.3. Recent Developments and Future Outlook
9.2.6. Moderna
9.2.6.1. Company Overview
9.2.6.2. Financial Information
9.2.6.3. Pipeline Overview
9.2.6.4. Recent Developments and Future Outlook
9.2.7. Providence Therapeutics
9.2.7.1. Company Overview
9.2.7.2. Pipeline Overview
9.2.7.3. Recent Developments and Future Outlook
9.2.8. Suzhou Abogen Biosciences
9.2.8.1. Company Overview
9.2.8.2. Pipeline Overview
9.2.8.3. Recent Developments and Future Outlook
9.3. Other Leading Players in mRNA Vaccine and Therapeutics Market
9.3.1. Gennova Biopharmaceuticals
9.3.1.1. Company Overview
9.3.1.2. Pipeline Overview
9.3.2. Innovac Therapeutics
9.3.2.1. Company Overview
9.3.2.2. Pipeline Overview
9.3.3. Kernal Biologics
9.3.3.1. Company Overview
9.3.3.2. Pipeline Overview
9.3.4. Pantherna Therapeutics
9.3.4.1. Company Overview
9.3.4.2. Pipeline Overview
9.3.5. pHion Therapeutics
9.3.5.1. Company Overview
9.3.5.2. Pipeline Overview
9.3.6. Recode Therapeutics
9.3.6.1. Company Overview
9.3.6.2. Pipeline Overview
9.3.7. Rejuvenation Technologies
9.3.7.1. Company Overview
9.3.7.2. Pipeline Overview
9.3.8. RNACure
9.3.8.1. Company Overview
9.3.8.2. Pipeline Overview
9.3.9. RNAimmune
9.3.9.1. Company Overview
9.3.9.2. Pipeline Overview
9.3.10. Strand Therapeutics
9.3.10.1. Company Overview
9.3.10.2. Pipeline Overview
9.3.11. Turn Biotechnologies
9.3.11.1. Company Overview
9.3.11.3. Pipeline Overview
9.3.12. Walvax Biotechnology
9.3.12.1. Company Overview
9.3.12.2. Pipeline Overview
9.3.13. Ziphius Vaccines
9.3.13.1. Company Overview
9.3.13.2. Pipeline Overview
10. BIG PHARMA INITIATIVES
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. mRNA Related Initiatives of Big Pharmaceutical Players
10.3.1. Analysis by Portfolio Diversity
10.3.2. Analysis by Phase of Development
10.3.3. Analysis by Target Therapeutic Area
10.4. Benchmarking Analysis: Big Pharma Players
10.4.1. Spider Web Analysis: Amgen
10.4.2. Spider Web Analysis: AstraZeneca
10.4.3. Spider Web Analysis: Bayer
10.4.4. Spider Web Analysis: BioNTech
10.4.5. Spider Web Analysis: Eli Lilly
10.4.6. Spider Web Analysis: Gilead Sciences
10.4.7. Spider Web Analysis: GlaxoSmithKline
10.4.8. Spider Web Analysis: Merck
10.4.9. Spider Web Analysis: Moderna
10.4.10. Spider Web Analysis: Novartis
10.4.11. Spider Web Analysis: Novo Nordisk
10.4.12. Spider Web Analysis: Pfizer
10.4.13. Spider Web Analysis: Roche
10.4.14. Spider Web Analysis: Sanofi
10.4.15. Spider Web Analysis: Takeda
10.5. Concluding Remarks
11. START-UP HEALTH INDEXING
11.1. Chapter Overview
11.2. Start-ups focused on mRNA Vaccine and Therapeutics
11.2.1. Analysis by Location of Headquarters
11.3. Benchmarking of Start-ups
11.4. Start-up Health Indexing
11.4.1. Analysis by Supplier Strength
11.4.2. Analysis by Pipeline Maturity
11.4.3. Analysis by Pipeline Strength
11.4.4. Analysis by Financial Investments
11.4.5. Analysis by Partnership Activity
11.4.6. Start-ups Health Indexing: Roots Analysis Perspective
12. CLINICAL TRIAL ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. mRNA Vaccine and Therapeutics: Clinical Trial Analysis
12.3.1. Analysis by Trial Registration Year
12.3.2. Analysis by Trial Status
12.3.3. Analysis by Trial Phase
12.3.4. Analysis by Trial Registration Year and Trial Status
12.3.5. Analysis by Trial Registration Year and Trial Phase
12.3.6. Analysis by Trial Status and Trial Phase
12.3.7. Analysis of Enrolled Patient Population by Trial Registration Year
12.3.8. Analysis by Study Design
12.3.9. Analysis by Type of Sponsor / Collaborator
12.3.10. Most Active Players: Analysis by Number of Registered Trials
12.3.11. Analysis by Therapeutic Area
12.3.12. Analysis by Number of Registered Trials and Geography
12.3.13. Analysis by Number of Registered Trials, Trial Status and Geography
12.3.14. Analysis of Enrolled Patient Population by Geography
13. PARTNERSHIPS AND COLLABORATIONS
13.1. Chapter Overview
13.2. Partnership Models
13.3. mRNA Vaccine and Therapeutics: Partnerships and Collaborations
13.3.1. Analysis by Year of Partnership
13.3.2. Analysis by Type of Partnership
13.3.3. Analysis by Year and Type of Partnership
13.3.4. Analysis by Therapeutic Area
13.3.5. Analysis by Type of Partnership and Therapeutic Area
13.3.6. Most Active Players: Analysis by Number of Partnerships
13.3.7. Analysis by Geography
13.3.7.1. Intercontinental and Intracontinental Agreements
13.3.7.2. Local and International Agreements
14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Types of Funding
14.3. mRNA Vaccine and Therapeutics: Funding and Investments
14.3.1. Analysis by Year of Funding
14.3.2. Analysis by Amount Invested
14.3.3. Analysis by Type of Funding
14.3.4. Analysis by Year and Type of Funding
14.3.5. Analysis of Funding Instances and Amount Invested by Therapeutic Area
14.3.6. Analysis by Geography
14.3.7. Most Active Players: Analysis by Number of Funding Instances
14.3.8. Most Active Players: Analysis by Total Amount Raised
14.3.9. Most Active Investors: Analysis by Number of Funding Instances
14.3.10. Analysis of Amount Invested by Year and Type of Funding
15. PATENT ANALYSIS
15.1. Chapter Overview
15.2. Scope and Methodology
15.3. mRNA Vaccine and Therapeutics: Patent Analysis
15.3.1. Analysis by Type of Patent
15.3.2. Analysis by Patent Publication Year
15.3.3. Analysis of Granted Patents by Publication Year
15.3.4. Analysis of Patent Applications by Publication Year
15.3.5. Analysis of Granted Patents and Patent Applications by Publication Year
15.3.6. Analysis by Publication Year and Type of Applicant
15.3.7. Analysis by Patent Jurisdiction
15.3.8. Analysis by Patent Age
15.3.9. Analysis by CPC Symbols
15.3.10. Leading Players: Analysis by Number of Patents
15.3.11. Leading Inventors: Analysis by Number of Patents
15.4. Patent Benchmarking Analysis
15.4.1. Analysis of Patent Characteristics (CPC Codes) by Leading Industry Players
15.5. mRNA Vaccine and Therapeutics: Patent Valuation Analysis
16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
16.1. Chapter Overview
16.2. Market Drivers
16.3. Market Restraints
16.4. Market Opportunities
16.5. Market Challenges
16.6. Conclusion
17. GLOBAL mRNA VACCINE AND THERAPEUTICS MARKET
17.1. Chapter Overview
17.2. Assumptions and Methodology
17.3. Global mRNA Vaccine and Therapeutics Market, till 2035
17.3.1. Scenario Analysis
17.3.1.1. Conservative Scenario
17.3.1.2. Optimistic Scenario
17.4. Key Market Segmentations
18. mRNA VACCINE AND THERAPEUTICS MARKET, BY APPLICATION AREA
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. mRNA Vaccine and Therapeutics Market: Distribution by Application Area, 2024, 2028 and 2035
18.3.1. mRNA Vaccine and Therapeutics Market for COVID-19, till 2035
18.3.2. mRNA Vaccine and Therapeutics Market for Other Indications, till 2035
18.4. Data Triangulation and Validation
19. mRNA VACCINE AND THERAPEUTICS MARKET, BY TARGET DISEASE INDICATION
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. mRNA Vaccine and Therapeutics Market: Distribution by Target Disease Indication, 2026, 2030 and 2035
19.3.1. mRNA Vaccine and Therapeutics Market for Influenza, till 2035
19.3.2. mRNA Vaccine and Therapeutics Market for Respiratory Syncytial Virus Infection, till 2035
19.3.3. mRNA Vaccine and Therapeutics Market for Cytomegalovirus Disease, till 2035
19.4. Data Triangulation and Validation
20. mRNA VACCINE AND THERAPEUTICS MARKET, BY GEOGRAPHICAL REGIONS
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. mRNA Vaccine and Therapeutics Market: Distribution by Geographical Regions, 2024, 2028 and 2035
20.3.1. mRNA Vaccine and Therapeutics Market in North America, till 2035
20.3.1.1. mRNA Vaccine and Therapeutics Market in the US, till 2035
20.3.1.2. mRNA Vaccine and Therapeutics Market in Canada, till 2035
20.3.2. mRNA Vaccine and Therapeutics Market in Europe, till 2035
20.3.2.1. mRNA Vaccine and Therapeutics Market in Germany, till 2035
20.3.2.2. mRNA Vaccine and Therapeutics Market in the UK, till 2035
20.3.2.3. mRNA Vaccine and Therapeutics Market in France, till 2035
20.3.2.4. mRNA Vaccine and Therapeutics Market in Italy, till 2035
20.3.2.5. mRNA Vaccine and Therapeutics Market in Spain, till 2035
20.3.2.6. mRNA Vaccine and Therapeutics Market in Belgium, till 2035
20.3.3. mRNA Vaccine and Therapeutics Market in Aisa-Pacific, till 2035
20.3.3.1. mRNA Vaccine and Therapeutics Market in China, till 2035
20.3.3.2. mRNA Vaccine and Therapeutics Market in India, till 2035
20.3.3.3. mRNA Vaccine and Therapeutics Market in Japan, till 2035
20.3.3.4. mRNA Vaccine and Therapeutics Market in Philippines, till 2035
20.3.3.5. mRNA Vaccine and Therapeutics Market in Australia, till 2035
20.3.4. mRNA Vaccine and Therapeutics Market in Latin America, till 2035
20.3.4.1. mRNA Vaccine and Therapeutics Market in Brazil, till 2035
20.3.5. mRNA Vaccine and Therapeutics Market in Rest of the World, till 2035
20.4. Data Triangulation and Validation
21. CONCLUSION
22. EXECUTIVE INSIGHTS
22.1. Chapter Overview
22.2. Canvax
22.2.1. Company Snapshot
22.2.2. Interview Transcript: Business Development Manager
22.3. eTheRNA
22.3.1. Company Snapshot
22.3.2. Interview Transcript: Senior Director, Business Development
22.4. GC Biopharma
22.4.1. Company Snapshot
22.4.2. Interview Transcript: Team Leader
23. APPENDIX 1: TABULATED DATA
24. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
